Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic ...

In localized non-small cell lung cancer (NSCLC), a tumor's ability to use carbon from glucose to feed the tricarboxylic acid ...

1 More than three-quarters of lung cancers fall into the histological category of non-small cell lung cancer (NSCLC). Currently, 10% of patients with NSCLC present with symptomatic brain metastases, ...

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung ...

Association of Germline Pathogenic Variants in MUTYH and Other DNA Damage Response Genes With Lung Cancer Risk Among Non-Hispanic Whites and African Americans The ideas and opinions expressed in this ...

Panelists discuss individualized treatment selection for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on targeted therapies and personalized approaches to improve patient ...

Readers should contact the corresponding author with any comments related to Data Supplement materials. Supported by the donor funds from John Hallick and the MET Crusaders and the University of ...

Metastatic lung cancer can spread to any structure or organ in the body, including the brain, liver, lymph nodes, and adrenal glands. It is also known as stage 4 non-small cell lung cancer (NSCLC).

Ridgefield, Conn., U.S., and Ingelheim, Germany <li /> Zongertinib would be the first orally administered, targeted therapy for ...

The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.

The FDA granted RMAT designation to nogapendekin alfa and CAR-NK for reversing lymphopenia in patients with cancer, with ...